Effect of Kohlrabi on prevention of renal stone

Effect of Kohlrabi’s juice on urinary concentration of oxalate, calcium, uric acid, citrate and crystals in patients with history of renal stone.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017021028003N2

Enrollment

Registered

2017-03-08

Start date

2017-03-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal stone. Calculus of kidney-Nephrolithiasis NOS-Renal calculus or stone-Staghorn calculus-Stone in kidney

Interventions

Intervention 1: Control group: placebo (vehicle syrup – 10 mg/kg/day for 2 weeks) / patients with history of nephrolithiasis (n=37). Intervention 2: Intervention group: oral drug of “Kohlrabi” (Brassi

Treatment - Drugs

Control group: placebo (vehicle syrup – 10 mg/kg/day for 2 weeks) / patients with history of nephrolithiasis (n=37)

Intervention group: oral drug of “Kohlrabi” (Brassica oleracea gongylodes) (10mg/kg/day for 2 weeks) / patients with history of nephrolithiasis (n=37)

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-Prehension of Informed consent for participation in the study 2-Subjects without special disease and disusing of any traditional or industrial drug. 3-Patients with history of recurrent renal stone: within the study and 6-8 weeks before initiation of it, ought not to use drug associated with decreasing recurrence of renal stone and/or superposed as instance of any urologic procedures such as TUL, PCNL & ESWL. 4-Disusing of warfarin drug and vitamin supplements in all groups. 5-Impassibility to Brassica oleracea in all groups. Exclusion criteria: 1-Patient disinclination for continuance of participation in the study. 2-Incidenting of sensitivity or any adverse reaction to utilized drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Urinary concentration of oxalate. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of calcium. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of uric acid. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of citrate. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary crystals. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.	—

Measure

Time frame

Urinary concentration of oxalate. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of calcium. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of uric acid. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary concentration of citrate. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.;Urinary crystals. Timepoint: 0 & 14th days of study. Method of measurement: 24-hour urine collection test.

—

Secondary

Measure	Time frame
Size of renal stone. Timepoint: 0 & 14th days of study. Method of measurement: Abdominopelvic CT scan without contrast.;Serum cratinine. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;BUN. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;ALT. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;AST. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Serum calcium. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Serum phosphore. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Urine PH. Timepoint: 0 & 14th days of study. Method of measurement: Urine test.	—

Measure

Time frame

Size of renal stone. Timepoint: 0 & 14th days of study. Method of measurement: Abdominopelvic CT scan without contrast.;Serum cratinine. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;BUN. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;ALT. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;AST. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Serum calcium. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Serum phosphore. Timepoint: 0 & 14th days of study. Method of measurement: Blood test.;Urine PH. Timepoint: 0 & 14th days of study. Method of measurement: Urine test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSanaz Taherpour

Ahwaz Jundishapour University of medical sciences

Taherpoursanaz@gmail.com-

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026